To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: IND Filed with FDA for New ANTICORT AIDS Treatment URL: http://www.pslgroup.com/dg/1E4E2.htm Doctor's Guide February 11, 1997
February 11, 1997, Las Vegas, Nevada -- Steroidogenesis Inhibitors, Inc. (SII) announced today it has submitted to the U.S. Food and Drug Administration (FDA) an Investigational New Drug (IND) Application for approval to commence Phase II human studies of ANTICORT (procaine HCI) for the treatment of HIV infected individuals. As proposed, a double-blind study of ANTICORT in connection with the treatment of asymptomatic, previously untreated HIV infected individuals will be conducted at the Martin Luther King Medical Center of the Charles R. Drew University of Medicine and Science in Los Angeles. The study will include HIV infected subjects with CD4 counts of 300-600 and HIV viral loads of more than 10,000 copies. In related news, SII in collaboration with Prof. E.A. Nunez, Chairman of the Department of Biochemistry at the University of Paris Medical School, announced it will host the second International Conference on Cortisols and Anticortisols, November 9-13, 1997 in Las Vegas Nevada. The first conference, held in Paris in June, 1996 was attended by university and research representatives from the U.S., France, Italy, Holland, India and the U.K. Due to increasing interest in the study of anticortisols for the treatment of AIDS and other diseases, participants from at least 20 countries are expected to attend this year's conference. Steroidogenesis Inhibitors, Inc. (SII) is a pharmaceutical R&D company engaged in the development of new drugs called anti-cortisols or steroidogenesis inhibitors which are used for the treatment of viral, infectious diseases (AIDS, hepatitis) and cancer. These otherwise unrelated diseases have in common the presence of elevated levels of cortisol, a hormone which suppresses the human immune system. In AIDS, ANTICORT may potentially stimulate the immune system in both HIV positive and AIDS patients previously unresponsive to other therapies. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.